Alto Neuroscience Files 8-K: Material Agreement & Equity Sales

Ticker: ANRO · Form: 8-K · Filed: 2024-07-29T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation, equity-sale

Related Tickers: ALTO

TL;DR

Alto Neuro just dropped an 8-K – new debt, equity sales, and financial docs filed.

AI Summary

On July 24, 2024, Alto Neuroscience, Inc. entered into a Material Definitive Agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits.

Why It Matters

This filing indicates significant corporate actions, including new financial obligations and equity transactions, which could impact the company's financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and unregistered equity sales, which can introduce financial obligations and dilution risks.

Key Players & Entities

FAQ

What type of Material Definitive Agreement did Alto Neuroscience enter into?

The filing indicates the entry into a Material Definitive Agreement that creates a direct financial obligation for the registrant, but the specific details of the agreement are not provided in this summary.

What is the significance of the 'Creation of a Direct Financial Obligation' item?

This item signifies that Alto Neuroscience has undertaken a new financial commitment or debt, which will appear on its balance sheet.

What information is provided regarding unregistered sales of equity securities?

The filing notes that there were unregistered sales of equity securities, but the specifics of the sale, such as the amount or price, are not detailed in this summary.

What is the filing date and the period of report for this 8-K?

The filing was made as of July 29, 2024, and the earliest event reported was on July 24, 2024.

Where is Alto Neuroscience, Inc. headquartered?

Alto Neuroscience, Inc. is headquartered at 650 Castro Street, Suite 450, Mountain View, CA 94041.

From the Filing

0001999480-24-000025.txt : 20240729 0001999480-24-000025.hdr.sgml : 20240729 20240729161904 ACCESSION NUMBER: 0001999480-24-000025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240724 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240729 DATE AS OF CHANGE: 20240729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 241152627 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 8-K 1 alto-20240724.htm 8-K alto-20240724 0001999480 False 0001999480 2024-07-24 2024-07-24 0001999480 dei:FormerAddressMember 2024-07-24 2024-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 _____________________ ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ Delaware   001-41944 83-4210124 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 650 Castro Street, Suite 450 , Mountain View , CA 94041 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 650 ) 200-0412 369 South San Antonio Road , Los Altos , CA 94022 (Former name or former address, if changed since last report.) _____________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share ANRO New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 1.01    Entry into a Material Definitive Agreement. As of July 24, 2024 (the “Effective Date”), Alto Neuroscience, Inc. (the “Company”) entered into a convertible loan agreement (the “Grant Agreement”) with The Wellcome Trust Limited (“Wellcome”), pursuant to which the Company received a funding award to support the Company’s Phase 2b clinical trial evaluating ALTO-100 in patients with bipolar depression (the “Clinical Trial&#

View on Read The Filing